Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


EyeBrain appoints business developer for Northern Europe

Neurological disease diagnostic specialist plans to bring its standardized medical eye movement exploration device to patients across Europe

Ivry-sur-Seine, France, March 14th, 2011 - EyeBrain, a developer of medical devices for the early diagnosis of neurological diseases, today announced the appointment of Savita Bernal as business developer for Northern Europe. She will be responsible for the development of commercial and scientific activities in the UK, Ireland and the Nordic countries. This is the first of a number of appointments to cover all European regions. They will focus on making sure the EyeBrain offer meets the differing requirements of national health authorities in Europe.

EyeBrain recently announced the availability of its eye-tracking system, the Mobile Eye Brain Tracker (Mobile EBT), which offers the efficient early diagnosis of Parkinson-plus diseases. The device, which is already CE market, has been available in France, Belgium and Luxembourg since June 2010, and is expected to be introduced to the UK and Irish markets in the first half of 2011, followed by the Nordic regions before the end of the year. Bernal’s primary task will be to support the launch of the new medical device, which can standardize medical eye movement exploration, in Northern Europe.

Bernal (30) joins EyeBrain from Ernst & Young Advisory, where her most recent position was external consultant. Prior to this, she acted as senior consultant on the life sciences sector. She holds a PhD in Cognitive Neuroscience, an MSc in Cognitive Science, an MSc in Cellular and Molecular Biology, as well as a Masters Degree in Project Management from the HEC Business School.

“We are really pleased to welcome Savita on board as she has all the qualities needed to ensure EyeBrain’s success in Northern European markets,” said Serge Kinkingnehun, Founder, CEO and Scientific Director of EyeBrain. “She is not only able to communicate with neurologists and ophthalmologists through her high-level scientific knowledge, but also has extensive experience in managing the marketing aspects of business development.”

The Mobile EBT is a medical eye tracker for neurologists. It has proven its efficacy in helping diagnose and differentiate between the various Parkinson-plus syndromes, a difficult task due to the similarity of syndromes. Unlike research eye trackers already on the market, the Mobile EBT provides a complete clinical solution, and produces a medical report presenting the automatically analyzed data.

About EyeBrain SA
EyeBrain develops and manufactures medical devices for the early diagnosis of neurological diseases. EyeBrain tools are based on oculomotricity. The recording and analysis of eye movements using sophisticated proprietary algorithms allows the testing of specific areas of the brain. The speed and accuracy of EyeBrain technology represents a true breakthrough in the diagnosis of neurological diseases. For the first time, clinicians can rely on a simple set of ocular movements parameters to discriminate between very similar syndromes such as PSP (progressive supranuclear palsy) and CBD (cortico-basal degeneration). The test is easily administered, non-invasive, and provides results in less than 20 minutes at a very low cost.
The Eye Brain Tracker (EBT) provides a complete solution including a helmet, a computer and two screens plus the software needed for stimulation and analysis. Used as part of normal clinical routine, the EBT can provide valuable help in early characterization of the Parkinson-plus diseases. EyeBrain is also working on the diagnosis of multiple sclerosis (MS).
EyeBrain has obtained an impressive range of regulatory approvals. EBT is the first device of its kind in the world to have obtained CE marking, the company has received ISO 9001 certification and the oculomotricity examination is reimbursed by French social security.

Founded in 2008, EyeBrain is based in the Paris region and currently has 15 employees. The company raised EUR 1.2 million in 2009 from CapDecisif and G1J and is already generating revenues through sales of its device. The company has collaboration agreements with Inserm, the CNRS, AP-HP and the Paris Descartes University.
For further information:

For further information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Juliette dos Santos
Tel: +33 1 56 54 07 00 /

Publisher Contact Information:

+33 1 56 54 07 00

Company profile of e(ye)BRAIN
Past press releases of e(ye)BRAIN.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Mar 23€2.0MInternet services
Mar 23€1.5MInternet services
Mar 23€110.0MInternet commerce
Mar 21€1.9MBusiness applications
Mar 20€1.0MInternet commerce
Mar 20€12.0ME-Commerce

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.